Evotec (ETR:EVT) Trading Down 0.9% – Here’s Why

Evotec SE (ETR:EVT) shares traded down 0.9% during trading on Tuesday . The stock traded as low as €3.42 and last traded at €3.42. 703,307 shares changed hands during trading, a decline of 48% from the average daily volume of 1,360,000 shares. The stock had previously closed at €3.45.

Evotec Trading Down 1.0%

The company has a debt-to-equity ratio of 55.38, a current ratio of 1.68 and a quick ratio of 2.97. The company has a market capitalization of $643.84 million, a price-to-earnings ratio of -3.75, a P/E/G ratio of 0.98 and a beta of 1.31. The business’s 50-day moving average price is €4.62 and its two-hundred day moving average price is €5.11.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.